Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
Akira OnoHaruyasu MurakamiTakashi SetoToshio ShimizuSawori WatanabeShigeru TakeshitaKentaro TakedaJunko ToyoshimaItsuro NagaseErkut BahceciMaiko MorishitaSatoshi MoritaMasahiro FukuokaKazuhiko NakagawaPublished in: Drugs in R&D (2020)
This study is registered at ClinicalTrials.gov under the identifier NCT01401504 on July 25, 2011.
Keyphrases